CRNX vs MANE
Crinetics Pharmaceuticals, Inc. vs Veradermics, Incorporated — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
69
Buy
VS
MANE
Veradermics, Incorporated
71
Buy
| Metric | CRNX | MANE |
|---|
| AI Score |
69
|
71
|
| Price |
$84.69
|
$112.65
|
| P/E Ratio |
-16.77×
|
-52.67×
|
| ROE |
-46.9%
|
57.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
0.0%
|
| Debt / Equity |
0.04×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
56.7
|
| Beta |
0.1302
|
1.3492
|
| Expected Upside |
—
|
+3.2%
|
AI Committee View
Current Innellis committee reasoning for CRNX versus MANE.
MANE leads by 2 points.
MANE scores 71/100 (Buy) versus CRNX at 69/100 (Buy).
CRNX Committee View
80% agreement
5 analysts
The primary driver is 3 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 90 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 90 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
MANE Committee View
80% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Risk/reward is unfavorable: 22.3% downside vs 3.2% upside.